Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -26% Improvement Relative Risk Vitamin D for COVID-19  Zangeneh et al.  ICU PATIENTS Is very late treatment with vitamin D beneficial for COVID-19? Retrospective study in Iran Higher mortality with vitamin D (not stat. sig., p=0.4) c19early.org Zangeneh et al., Obesity Medicine, May 2022 Favors vitamin D Favors control

Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of Amir Al-Momenin Hospital in Arak – 2021

Zangeneh et al., Obesity Medicine, doi:10.1016/j.obmed.2022.100420
May 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 119 studies, recognized in 7 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 193 ICU patients in Iran, showing no significant difference with vitamin D treatment.
Cholecalciferol was used in this study. Meta analysis shows that late stage treatment with calcitriol / calcifediol (or paricalcitol, alfacalcidol, etc.) is more effective than cholecalciferol: 65% [41‑79%] lower risk vs. 39% [26‑49%] lower risk. Cholecalciferol requires two hydroxylation steps to become activated - first in the liver to calcifediol, then in the kidney to calcitriol. Calcitriol, paricalcitol, and alfacalcidol are active vitamin D analogs that do not require conversion. This allows them to have more rapid onset of action compared to cholecalciferol. The time delay for cholecalciferol to increase serum calcifediol levels can be 2-3 days, and the delay for converting calcifediol to active calcitriol can be up to 7 days.
This is the 80th of 119 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 116 sextillion). 29 studies are RCTs, which show efficacy with p=0.0000035.
This study is excluded in the after exclusion results of meta analysis: very late stage study using cholecalciferol instead of calcifediol or calcitriol.
Study covers vitamin C, vitamin D, zinc, remdesivir, and famotidine.
risk of death, 26.0% higher, HR 1.26, p = 0.40, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zangeneh et al., 13 May 2022, retrospective, Iran, peer-reviewed, 3 authors, dosage not specified. Contact: mor.zangene62@gmail.com, touraj1416@gmail.com, a.sharifi1983@gmail.com, a_sharifi@goums.ac.ir.
This PaperVitamin DAll
Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of Amir Al-Momenin Hospital in Arak – 2021
Morteza Zangeneh, Touraj Valeh, Amrollah Sharifi
Obesity Medicine, doi:10.1016/j.obmed.2022.100420
Introduction: The potential risk of obesity on the severity of COVID-19 has been proposed. The main purpose of this study was to investigate the effect of BMI on the survival rate of COVID-19 patients admitted to the ICU. Methods & materials: Patients with COVID-19 admitted to ICU were included. Gender, height, weight, BMI, age, underlying disease status, prescribed drugs and nutritional supplements, and clinical and laboratory parameters at the beginning of admission were recorded. Death or discharge from the ICU and the days elapsed to these events were also reviewed and recorded. Data analysis was performed using the Cox regression model. Results: assessing 193 patients showed that BMI was not related to the survival rate even after adjusting for other potential confounding variables. It was shown that arterial oxygen saturation and taking Famotidine were the significant factors determining the time to event in these patients. Conclusion: The BMI at the time of ICU admission has no effect on survival rate and time to event in COVID-19 infected patients admitted to ICU.
Declaration of competing interest None.
References
Abbas, Fathy, Fawzy, Salem, Shawky et al., Obesity and susceptibility to severe outcomes following respiratory viral infection, Obes. Med
Andersen, Murphy, Fernandez, Impact of obesity and metabolic syndrome on immunity, Adv. Nutr
Brennan, Nadella, Zhao, Dima, Jordan-Martin et al., Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial, Gut
Cheng, Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?, Med. Drug Discov
Chiu, Shen, Lo, Chiu, Chen et al., Effect of famotidine on hospitalized patients with COVID-19: a systematic review and metaanalysis, PLoS One
Chowdhury, Alam, Rabbi, Rahman, Reza, Does higher body mass index increase COVID-19 severity? A systematic review and metaanalysis, Obes. Med
De Almeida Brasiel, The key role of zinc in elderly immunity: a possible approach in the COVID-19 crisis, Clin. Nutr. ESPEN
De Siqueira, Almeida, Zica, Brum, Barcelo et al., Impact of obesity on hospitalizations and mortality, due to COVID-19: a systematic review, Obes. Res. Clin. Pract
Emami, Akbari, Basirat, Zare, Javanmardi et al., The role of comorbidities on mortality of COVID-19 in patients with diabetes, Obes. Med
Fresán, Guevara, Elía, Albéniz, Burgui et al., Independent role of severe obesity as a risk factor for COVID-19 hospitalization: a Spanish population-based cohort study, Obesity
Giacomelli, Ridolfo, Milazzo, Oreni, Bernacchia et al., 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study, Pharmacol. Res
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy, JAMA
Houdek, Griffin, Ferguson, Wunder, Morbid obesity increases the risk of postoperative wound complications, infection, and repeat surgical procedures following upper extremity limb salvage surgery for soft tissue sarcoma, Hand (N Y)
Huang, Lu, Huang, Wang, Ling et al., Obesity in patients with COVID-19: a systematic review and meta-analysis, Obes. Res. Clin. Pract
Huang, Wang, Zheng, Liu, Chen et al., Letter to the Editor: obesity hypoventilation syndrome and severe COVID-19, Metabolism
Kang, Mortality rate of infection with COVID-19 in Korea from the perspective of underlying disease, Disaster Med. Public Health Prep
Li, Li, Zhang, Wang, Lighter et al., Obesity in patients younger than 60 Years is a risk factor for COVID-19 hospital admission, Infect. Dis. Poverty
Loffredo, Lucero, Chen, O'connell, Bergqvist et al., The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication, Sci. Rep
Louie, Acosta, Samuel, Schechter, Vugia et al., A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1), Clin. Infect. Dis
Mizumoto, Kagaya, Zarebski, Chowell, Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Euro Surveill
Muscogiuri, Pugliese, Barrea, Savastano, Colao, Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection, Metabol. Clin
Palaiodimos, Kokkinidis, Li, Karamanis, Ognibene et al., Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, Metabolism
Pranata, Lim, Yonas, Vania, Lukito et al., Body mass index and outcome in patients with COVID-19: a dose-response metaanalysis, Diabetes Metab
Rojas-Osornio, Cruz-Hernandez, Drago-Serrano, Campos-Rodriguez, Immunity to influenza: impact of obesity, Obes. Res. Clin. Pract
Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med
Rychter, Zawada, Ratajczak, Dobrowolska, Krela-Kazmierczak, Should patients with obesity be more afraid of COVID-19?, Obes. Rev
Sartaj Sohrab, Atkinson, Alawi, Azhar, Viral infection and obesity: current status and future prospective, Curr. Drug Metabol
Sattar, Mcinnes, Mcmurray, Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms, Circulation
Shrestha, Charkviani, Musurakis, Kansakar, Devkota et al., Type 2 diabetes is associated with increased risk of critical respiratory illness in patients COVID-19 in a community hospital, Obes. Med
Skalny, Rink, Ajsuvakova, Aschner, Gritsenko et al., Zinc and respiratory tract infections: perspectives for COVID-19, Int. J. Mol. Med
Sureshchandra, Marshall, Messaoudi, Impact of pregravid obesity on maternal and fetal immunity: fertile grounds for reprogramming, J. Leukoc. Biol
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Yates, Razieh, Zaccardi, Davies, Khunti, Obesity and risk of COVID-19: analysis of UK biobank, Prim. Care Diabetes
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit